A616 Response to Thalidomide in Patients with MM Following Disease Progression with Pomalidomide
Tariq I. Mughal(Tufts University), Mary E. Smith(National Institutes of Health), M. Kazmi(St Thomas' Hospital), Oliver Stewart, Matthew Streetly(King's College - North Carolina)
Cited by 1
Related Papers
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
|Blood|2018|421
Non-Hodgkin’s Lymphomas
|Journal of the National Comprehensive Cancer Network|2010|329
Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma
|Journal of Clinical Oncology|2004|315